GlassScriptPhysician profile
Richard Marquez
NPI 1306877766
$6,494.70
in general payments reported to CMS, 2019-2025
37 companies · $744 in 2025
The $744 reported for 2025 was more than what 75% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,058 · 2022: $2,982 · 2023: $372 · 2024: $339 · 2025: $744.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,455.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,454.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $975.74 | 2021-2025 | Ozempic |
| Abbvie INC. | $779.22 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $552.75 | 2021-2025 | Breztri, Airsupra, Farxiga |
| Janssen Pharmaceuticals, INC | $519.61 | 2021-2023 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $396.84 | 2022 | |
| Merck Sharp & Dohme LLC | $299.35 | 2021-2024 | Capvaxive, Gardasil 9, Gardasil |
| Lilly USA, LLC | $285.06 | 2021-2024 | Jardiance, Mounjaro |
| E.R. Squibb & Sons, L.L.C. | $256.23 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $220.11 | 2021 | |
| Gilead Sciences, INC. | $213.63 | 2023-2025 | |
| Amgen INC. | $196.34 | 2022-2025 | Evenity, Otezla, Repatha |
| Biohaven Pharmaceutical Holding Company LTD. | $193.38 | 2022 | |
| Esperion Therapeutics, INC. | $179.98 | 2021-2022 | |
| Corcept Therapeutics | $159.35 | 2021 | |
| Globus Medical, INC. | $158.79 | 2025 | Senza |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Althera Pharmaceuticals LLC | $137.86 | 2022 | |
| Phathom Pharmaceuticals, INC. | $124.99 | 2024 | Voquezna |
| Intuity Medical INC | $115.74 | 2022 | |
| Nevro Corp. | $87.52 | 2022-2023 | Senza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $86.76 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $82.62 | 2021 | |
| Amarin Pharma, INC. | $75.43 | 2021 | |
| Novartis Pharmaceuticals Corporation | $62.59 | 2021-2025 | |
| Glaxosmithkline, LLC. | $48.15 | 2021-2025 | Shingrix, Arexvy |
| Pfizer INC. | $41.55 | 2022-2025 | |
| Astellas Pharma US INC | $35.54 | 2021 | |
| Hologic Sales and Service, LLC | $35.05 | 2022 | |
| Eisai INC. | $23.81 | 2021 | |
| Si-Bone, INC. | $21.09 | 2021 | |
| Hikma Pharmaceuticals USA | $21.00 | 2022 | |
| Bigfoot Biomedical INC | $20.90 | 2022 | |
| Corium, LLC | $17.97 | 2022 | |
| Idorsia Pharmaceuticals US INC | $17.42 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.51 | 2021 | |
| Boston Scientific Corporation | $13.08 | 2023 | Ekosonic |
| Dexcom, INC. | $12.65 | 2021 | |
| Bausch Health US, LLC | $12.09 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Marquez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.